|92.94 -2 (-2.11%)||12-08 16:00|
|Targets||6-month :||111.43||1-year :||130.16|
|Resists||First :||95.41||Second :||111.43|
|Supports||First :||83.53||Second :||76.19|
|MAs||MA(5) :||94.01||MA(20) :||89.29|
|MA(100) :||88||MA(250) :||94.27|
|MACD||MACD :||2.4||Signal :||1.9|
|%K %D||K(14,3) :||86.3||D(3) :||89.8|
|52-week||High :||117.76||Low :||76.01|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BMRN ] has closed below upper band by 28.9%. Bollinger Bands are 52.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||94.44 - 94.93||94.93 - 95.36|
|Low:||91.18 - 91.74||91.74 - 92.22|
|Close:||92.01 - 92.97||92.97 - 93.79|
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||188 (M)|
|Shares Float||187 (M)|
|Held by Insiders||0.4 (%)|
|Held by Institutions||97.7 (%)|
|Shares Short||3,080 (K)|
|Shares Short P.Month||7,030 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||26|
|Profit Margin||6.3 %|
|Operating Margin||4.4 %|
|Return on Assets (ttm)||1.1 %|
|Return on Equity (ttm)||3.1 %|
|Qtrly Rev. Growth||15 %|
|Gross Profit (p.s.)||8.54|
|Sales Per Share||12.26|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||139 (M)|
|Levered Free Cash Flow||-12 (M)|
|Price to Book value||3.57|
|Price to Sales||7.57|
|Price to Cash Flow||126.35|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|